Vaccination Lowers Pneumonia Incidence Among Elderly People
A pneumococcal vaccine helps prevent pneumonia among people over the age of 65. Research among some 85,000 Dutch subjects shows that vaccination halves the number of hospitalizations due to infection with this bacterium. Researchers at University Medical Center (UMC) of Utrecht, in collaboration with Pfizer, published these results today in the New England Journal of Medicine. A guideline has been drafted in the U.S. that recommends that all elderly people receive the vaccine.
In the “Community-acquired pneumonia immunization Trial in Adults”, or CAPiTA for short, the effect of vaccine PCV13, which targets 13 strains of Streptococcus pneumoniae, the main cause of pneumonia, was studied. The vaccine’s efficacy in children has been known for some time. Since 2006, the pneumococcal vaccine has been part of the Dutch national vaccination program, which means that all infants are inoculated. Whether the medicine also offers protection for the elderly remained unknown to date.
In order to research this, over 42,500 senior citizens were administered the PCV13 vaccine from September 2008 to the end of January 2010. The same number of people were given a placebo. The four-year follow-up focused on whether the subjects were hospitalized with pneumonia or invasive pneumococcal disease. Involving over 2,000 general practitioners and 59 hospitals, this large-scale study was coordinated by Julius Clinical (a UMC Utrecht spin-off) and the UMC Utrecht in collaboration with Pfizer, who developed the vaccine.
During the study, 49 of those who had received the vaccine were hospitalized with pneumonia due to the type of S. pneumoniae, against which the vaccine is intended to offer protection. That is 45 percent less than in the group of elderly people who received the placebo: 90 patients from this group were hospitalized. The total number of hospitalizations due to pneumonia decreased by 5 percent; apart from S. pneumoniae, there are other bacteria and viruses that cause pneumonia. Marc Bonten, professor of Molecular Epidemiology of Infectious Diseases at the UMC Utrecht and research leader of the CAPiTA study explains, “It has now been demonstrated for the first time that a vaccine can prevent pneumonia in elderly people. The vaccine offers long-term protection: its effectiveness did not decrease in the four years of the study. If all people over the age of 65 were to be given PCV13, this would result in several hundred fewer hospitalizations in the Netherlands.”
Reference
Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med 2015;372:1114-25
For more information, please contact the press office of UMC Utrecht.
Phone: +31 88 7555 50 00
Email: press@umcutrecht.nl
About University Medical Center Utrecht
University Medical Center Utrecht (UMC Utrecht) belongs to the largest public healthcare institutions in the Netherlands. It was created in 2000 through the merger of Utrecht Academic Hospital, Wilhelmina Children’s Hospital and the Medical Faculty of Utrecht University. UMC Utrecht has the ambition to be a leading international healthcare provider, medical school and research institute that is exciting for its people, attractive to talent and embodies a culture of teamwork, innovation, sustainability and high performance. As a patient-centered organization, its 11,000 employees are dedicated to prevent disease, improve healthcare, develop new treatment methods and refine existing ones, with patient safety and quality as cornerstones. Strategic research programs are Brain, Child Health, Circulatory Health, Infection & Immunity, Personalized Cancer Care and Regenerative Medicine & Stem Cells. UMC Utrecht is embedded in a vibrant and entrepreneurial science community where knowledge about health, disease and healthcare is generated, validated, shared and applied. For more information, visit www.umcutrecht.nl or follow us on Twitter @UMCU_INTL.